fbpx

Day

December 8, 2015
Ness Ziona, Israel - Dec 7, 2015 - Atox Bio, developer of immunomodulatory therapeutics for rapidly-progressing infectious diseases in critically ill patients, today announced that it has enrolled the first patient in its Phase 3 study to evaluate AB103 - the first-ever candidate developed for the treatment of Necrotizing Soft Tissue Infections (NSTIs), also known...

News

Experienced neuroscientist at the helm of The Brain Prize
30. June 2020
Eight promising young researchers receive Lundbeck Foundation Fellowships
16. June 2020
Denmark Gets Its First Master’s Degree Programme in Neuroscience
4. June 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge